Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 15/20 | 0.66 |
| ▸ | ADRB2 | P07550 | 11/20 | 0.66 |
| ▸ | ADRB1 | P08588 | 11/20 | 0.66 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.66 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.66 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.66 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.66 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.66 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.66 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15382678 | 1.00 | ADRB3 (0.66) | ADRB3ADRB2ADRB1ADRA1DADRA1A | |
| SCHEMBL1770178 | 1.00 | ADRB3 (0.66) | ADRB3ADRB2ADRB1ADRA1DADRA1A | |
| SCHEMBL10085311 | 1.00 | ADRB3 (0.66) | ADRB3ADRB2ADRB1ADRA1DADRA1A | |
| SCHEMBL5458218 | 1.00 | ADRB3 (0.66) | ADRB3ADRB2ADRB1ADRA1DADRA1A | |
| SCHEMBL364457 | 1.00 | ADRB3 (0.66) | ADRB3ADRB2ADRB1ADRA1DADRA1A | |
| SCHEMBL7160000 | 1.00 | ADRB3 (0.66) | ADRB3ADRB2ADRB1ADRA1DADRA1A | |
| Hydrochloric Acid SCHEMBL7492283 | 0.99 | ADRB3 (0.65) | ADRB3ADRB2ADRB1ADRA1DADRA1A | |
| Hydrochloric Acid SCHEMBL7487214 | 0.99 | ADRB3 (0.65) | ADRB3ADRB2ADRB1ADRA1DADRA1A | |
| Hydrochloric Acid SCHEMBL7489762 | 0.99 | ADRB3 (0.65) | ADRB3ADRB2ADRB1ADRA1DADRA1A | |
| Hydrochloric Acid SCHEMBL7488236 | 0.99 | ADRB3 (0.65) | ADRB3ADRB2ADRB1ADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092509-A1 | Pharmaceutical Composition for Prevention or Treatment of Disease Associated with Tear Reduction | Kissei Pharmaceutical, Co. Ltd. (JP) | 2011-04-21 | — | — | US | claimed |
| EP-2123268-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF DISEASE ASSOCIATED WITH TEAR REDUCTION | Kissei Pharmaceutical Co., Ltd. (JP) | 2009-11-25 | — | — | EP | claimed |
| EP-3024474-B1 | COMPOSITIONS COMPRISING DESMOPRESSIN IN COMBINATION WITH A BETA-3 ADRENERGIC RECEPTOR AGONIST | SERENITY PHARMACEUTICALS LLC (US) | 2022-01-05 | — | — | EP | disclosed |
| US-10568927-B2 | Methods and compositions comprising desmopressin in combination with a beta-3-adrenergic receptor agonist | SERENITY PHARMACEUTICALS LLC (US) | 2020-02-25 | — | — | US | disclosed |
| US-9814753-B2 | Methods and compositions comprising desmopressin in combination with a beta-3-adrenergic receptor agonist | SERENITY PHARMACEUTICALS LLC (US) | 2017-11-14 | — | — | US | disclosed |
| EP-3024474-A1 | METHODS AND COMPOSITIONS COMPRISING DESMOPRESSIN IN COMBINATION WITH A BETA-3 ADRENERGIC RECEPTOR AGONIST | ALLERGAN, INC. (US) | 2016-06-01 | — | — | EP | disclosed |
| US-20150031613-A1 | METHODS AND COMPOSITIONS COMPRISING DESMOPRESSIN IN COMBINATION WTIH A BETA-3-ADRENERGIC RECEPTOR AGONIST | SERENITY PHARMACEUTICALS LLC | 2015-01-29 | — | — | US | disclosed |
| WO-2015013454-A1 | METHODS AND COMPOSITIONS COMPRISING DESMOPRESSIN IN COMBINATION WITH A BETA-3 ADRENERGIC RECEPTOR AGONIST | ALLERGAN, INC. (US) | 2015-01-29 | — | — | WO | disclosed |
| US-20110092509-A1 | Pharmaceutical Composition for Prevention or Treatment of Disease Associated with Tear Reduction | Kissei Pharmaceutical, Co. Ltd. (JP) | 2011-04-21 | — | — | US | disclosed |
| EP-2123268-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF DISEASE ASSOCIATED WITH TEAR REDUCTION | Kissei Pharmaceutical Co., Ltd. (JP) | 2009-11-25 | — | — | EP | disclosed |
| US-20090275626-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF NEUROGENIC PAIN | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-11-05 | — | — | US | disclosed |
| EP-1020458-B1 | OPTICALLY ACTIVE 1,4-BENZODIOXINE-2-CARBOXYLIC ACID DERIVATIVES AND PROCESS FOR PRODUCING THE SAME | NISSHIN PHARMA INC (JP) | 2008-05-07 | — | — | EP | disclosed |
| JP-2008007502-A | OBESITY-CURATIVE AGENT AND METHOD FOR TREATING AND PREVENTING OBESITY | KYORIN PHARMACEUT CO LTD | 2008-01-17 | — | — | JP | disclosed |
| US-20060084700-A1 | Use of a beta-3 agonist for the treatment of disorders of the prostate and of the lower urogenital tract | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-04-20 | — | — | US | disclosed |
| US-6509482-B2 | Chemical intermediates for synthesis of optical isomers useful as prophylactic and therapeutic agents for diabetes and hyperglycemia | NISSHIN PHARMA INC. (JP) | 2003-01-21 | — | — | US | disclosed |
| US-20020028957-A1 | Optically active 1,4-benzodioxin-2-carboxylic acid derivatives and process for producing the same | NISSHIN PHARMA INC. (JP) | 2002-03-07 | — | — | US | disclosed |
| US-6329533-B2 | CHEMICAL INTERMEDIATE FOR ANTIDIABETIC DRUG | NISSHIN PHARMA INC. (JP) | 2001-12-11 | — | — | US | disclosed |
| US-20010018529-A1 | Optically active 1,4-benzodioxin-2-carboxylic acid derivatives and process for producing the same | NISSHIN FLOUR MILLING CO., LTD. (JP) | 2001-08-30 | — | — | US | disclosed |
| US-6222050-B1 | AS CHEMICAL INTERMEDIATES USEFUL FOR SYNTHESIS OF (RRR)-OPTICAL ISOMERS OF 1,4-BENZODIOXIN-2-CARBOXYLIC ACID DERIVATIVES WHICH ARE USEFUL AS PROPHYLACTIC AND THERAPEUTIC AGENT FOR DIABETES, HYPERGLYCEMIA | NISSHIN FLOUR MILLING CO., LTD. (JP) | 2001-04-24 | — | — | US | disclosed |
| EP-1020458-A1 | OPTICALLY ACTIVE 1,4-BENZODIOXINE-2-CARBOXYLIC ACID DERIVATIVES AND PROCESS FOR PRODUCING THE SAME | Nisshin Flour Milling Co., Ltd. (JP) | 2000-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028957-A1 | Optically active 1,4-benzodioxin-2-carboxylic acid derivatives and process for producing the same | GPR119, CBR1, ADH1C | ADRB3 954/4885ADRB2 551/4885ADRB1 321/4885 |
| US-20010018529-A1 | Optically active 1,4-benzodioxin-2-carboxylic acid derivatives and process for producing the same | CBR1, GPR119, ADH1C | ADRB3 867/4885ADRB2 493/4885ADRB1 299/4885 |
| US-20060084700-A1 | Use of a beta-3 agonist for the treatment of disorders of the prostate and of the lower urogenital tract | ADRB3, ADRB2, ADRB1 | ADRB3 1/4885ADRB2 2/4885ADRB1 3/4885 |
| US-20110092509-A1 | Pharmaceutical Composition for Prevention or Treatment of Disease Associated with Tear Reduction | SSB, CUTA, HRH2 | ADRB3 1960/4885ADRB2 1315/4885ADRB1 1498/4885 |
| US-20090275626-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF NEUROGENIC PAIN | ADRB3, ALOX5, LTB4R | ADRB3 1/4885ADRB2 26/4885ADRB1 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.